Neoepitope (at C-terminus of 3/4 peptide) generated through cleavage of type-II collagen by collagenases
Store urine samples at 4ºC for 24 hours, for longer storage store at -20°C. Frozen samples should be thawed gradually at room temperature; vortex and centrifuge or allow sedimentation for a minimum of 30 minutes.
uC2C levels in urine vary with age.
In normal healthy individuals:
uC2C levels are very high in growing babies and children,
and decrease substantially in healthy adults.
Active exercise may increase the uC2C levels.
|Product name||C2C HUSA™|
|Incubation time||2 hours|
|Sample volume||30 µl|
Second Morning void urine is recommended, but spot urine samples may be used.
No cross reactivity with corresponding neoepitope peptides derived from collagen I and collagen III is detected.
Detection limit: 70 pg/ml
The C2C HUSA™ is a colour-monitoring sandwich immunoassay that measures the C2C neoepitope fragments longer than 20 amino acids, present in human urine samples. It has been reported that a 45-mer peptide is the most abundant C2C neoepitope fragment in human urine samples (Nemirovskiy et al., 2007)
A strong correlation of increased uC2C levels with increased risks of having Osteoarthritis (OA) and/or Rheumatoid Arthritis (RA).
- The C2C is a specific biomarker for cartilage degradation.
- The C2C biomarker can be used to monitor drug intervention in pre-clinical and clinical research:
- C2C levels increase with addition of MMP enzymes
- C2C levels are modulated with addition of MMP inhibitors
- Increased uC2C levels appear to be predictive of ROA and pre-ROA